Charlie's Holdings Swings to Profit on $7.5M IP Sale, Revenue Jumps 77%

TL;DR

**CHUC's $7.5M IP sale is a lifeline, but FDA regulatory headwinds are a major red flag for long-term viability.**

AI Summary

Charlie's Holdings, Inc. (CHUC) reported a significant turnaround for the nine months ended September 30, 2025, achieving a net income of $4.368 million, a substantial improvement from a net loss of $3.034 million in the prior year period. This was primarily driven by a gain of $7.500 million from the sale of intellectual property, specifically 16 PACHA synthetic products and related assets, to R.J. Reynolds Vapor Company. Product revenue also saw a robust increase, reaching $11.934 million for the nine months ended September 30, 2025, up from $6.718 million in the same period of 2024, representing a 77.6% increase. Despite this, the company still utilized $6.172 million in cash from operating activities. Working capital improved dramatically to $3.079 million as of September 30, 2025, from a deficit of $1.855 million at December 31, 2024. The company faces ongoing regulatory risks, including a Marketing Denial Order (MDO) from the FDA for certain PMTAs received on October 28, 2025, though a temporary administrative stay was granted on November 10, 2025. Additionally, the company plans to wind down its Don Polly division in Q4 2025.

Why It Matters

For investors, CHUC's pivot to profitability, largely due to the $7.5 million intellectual property sale to R.J. Reynolds Vapor Company, provides a much-needed cash infusion and improved working capital, addressing immediate going concern doubts. However, the ongoing FDA regulatory challenges, including a recent MDO and the uncertainty surrounding its SBX Metatine products, pose significant long-term risks that could impact future revenue streams and market access. The competitive landscape in the nicotine and vapor product industry is heavily influenced by regulatory actions, and CHUC's ability to navigate these will determine its market position against larger players. Employees and customers of the Don Polly division will be directly affected by its planned wind-down in Q4 2025.

Risk Assessment

Risk Level: high — The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern' despite recent improvements. The FDA issued a Marketing Denial Order (MDO) on October 28, 2025, for certain PMTAs, which, if not overturned, would require the company to cease selling affected products. Furthermore, the regulatory status of its new SBX Metatine products is uncertain, with potential for FDA enforcement actions.

Analyst Insight

Investors should exercise extreme caution and closely monitor the outcomes of CHUC's legal challenges against the FDA's MDO and any regulatory developments concerning its SBX Metatine products. Given the high regulatory risk and reliance on one-time asset sales for profitability, a 'wait and see' approach is advisable before considering any investment.

Financial Highlights

debt To Equity

N/A

revenue

$11.934M

operating Margin

N/A

total Assets

$10.558M

total Debt

$7.319M

net Income

$4.368M

eps

N/A

gross Margin

24.76%

cash Position

$1.150M

revenue Growth

+77.6%

Revenue Breakdown

Key Numbers

• $4.368M — Net Income (for the nine months ended September 30, 2025, compared to a $3.034M net loss in 2024)
• $7.500M — Gain on Sale of Intellectual Property (from the sale of PACHA synthetic products to R.J. Reynolds Vapor Company)
• $11.934M — Product Revenue (for the nine months ended September 30, 2025, up from $6.718M in 2024)
• 77.6% — Revenue Increase (year-over-year for the nine months ended September 30, 2025)
• $6.172M — Net Cash Used in Operating Activities (for the nine months ended September 30, 2025)
• $3.079M — Working Capital (as of September 30, 2025, an increase from a $1.855M deficit at December 31, 2024)
• $1,150 — Cash (as of September 30, 2025, up from $211 at December 31, 2024 (in thousands))
• $2,042,000 — Loss from Operations (for the nine months ended September 30, 2025)

Key Players & Entities

• Charlie's Holdings, Inc. (company) — registrant
• R.J. Reynolds Vapor Company (company) — buyer of intellectual property
• FDA (regulator) — regulatory body for nicotine products
• Don Polly (company) — consolidated variable interest entity being wound down
• United States Court of Appeals for the Fifth Circuit (regulator) — court granting temporary administrative stay
• Charlie's Chalk Dust, LLC (company) — wholly owned subsidiary
• PACHA (company) — brand of synthetic products sold
• SBX (company) — brand of new disposable vape products

FAQ

Risk Factors

• FDA Marketing Denial Order (MDO) [high — regulatory]: The company received an MDO from the FDA for certain PMTAs on October 28, 2025. While a temporary administrative stay was granted on November 10, 2025, this represents a significant ongoing regulatory risk that could impact future product sales and operations.
• Winding Down of Don Polly Division [medium — operational]: Charlie's Holdings plans to wind down its Don Polly division in Q4 2025. This operational change may involve restructuring costs and impact the company's product portfolio and future revenue streams.
• Cash Burn from Operations [medium — financial]: Despite improved net income, the company utilized $6.172 million in cash from operating activities for the nine months ended September 30, 2025. This indicates ongoing cash flow challenges that require careful management.

Industry Context

The vapor and tobacco product industry is highly regulated, with evolving FDA oversight impacting product approvals and market access. Companies are increasingly focused on product innovation and navigating complex compliance landscapes. The market also sees consolidation and strategic partnerships, as evidenced by the IP sale to R.J. Reynolds Vapor Company.

Regulatory Implications

Charlie's Holdings faces significant regulatory headwinds, particularly from the FDA's MDO. The temporary stay provides a brief window, but the long-term impact of these regulatory actions on product availability and market strategy remains a key concern.

What Investors Should Do

1. Monitor FDA regulatory developments closely, especially regarding the MDO and any further actions or appeals.
2. Analyze the sustainability of revenue growth beyond the one-time IP sale gain, focusing on core product performance.
3. Assess the impact of the Don Polly division wind-down on future profitability and operational efficiency.
4. Evaluate the company's cash flow generation and its ability to fund operations without further cash burn.

Key Dates

• 2025-09-30: End of Nine Months Reporting Period — Key period for financial results, showing a significant turnaround in net income and revenue growth.
• 2025-10-28: FDA Marketing Denial Order (MDO) — A critical regulatory event that poses a significant risk to the company's product lines.
• 2025-11-10: Temporary Administrative Stay Granted on MDO — Provides a temporary reprieve from the MDO, offering a short window for the company to address regulatory concerns.
• 2025-12-31: Planned Wind Down of Don Polly Division — Marks a strategic shift in the company's operational focus and product offerings.

Glossary

PMTAs

Premarket Tobacco Product Applications, which are required by the FDA for new tobacco products to be legally marketed. (The FDA's action on PMTAs directly impacts the company's ability to sell certain products.)

MDO

Marketing Denial Order, issued by the FDA to prohibit the marketing of a tobacco product for which a PMTA has been submitted but not approved. (This is a critical regulatory action that can halt sales of specific products.)

Working Capital

The difference between a company's current assets and current liabilities. It indicates the company's short-term financial health and operational efficiency. (A significant improvement in working capital suggests better short-term liquidity and operational management.)

Gain on Sale of Intellectual Property

Profit realized from selling intangible assets like patents, trademarks, or proprietary technology. (This was a major contributor to the company's net income turnaround in the current period.)

Year-Over-Year Comparison

Charlie's Holdings has demonstrated a dramatic financial turnaround compared to the prior year period. Revenue has surged by 77.6% to $11.934 million, and the company has shifted from a net loss of $3.034 million to a net income of $4.368 million, largely due to a significant gain from intellectual property sale. Working capital has also improved substantially, moving from a deficit to a positive balance. However, operating cash flow remains negative, and new regulatory risks, such as the FDA's MDO, have emerged.

Filing Documents

• chuc20250930_10q.htm (10-Q) — 1151KB
• ex_886248.htm (EX-31.1) — 12KB
• ex_886247.htm (EX-31.2) — 12KB
• ex_886246.htm (EX-32.1) — 5KB
• ex_886245.htm (EX-32.2) — 5KB
• 0001437749-25-035731.txt ( ) — 5943KB
• chuc-20250930.xsd (EX-101.SCH) — 56KB
• chuc-20250930_def.xml (EX-101.DEF) — 407KB
• chuc-20250930_lab.xml (EX-101.LAB) — 331KB
• chuc-20250930_pre.xml (EX-101.PRE) — 441KB
• chuc-20250930_cal.xml (EX-101.CAL) — 41KB
• chuc20250930_10q_htm.xml (XML) — 775KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION ITEM 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 2 Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Stockholders' Deficit (unaudited) for the three and nine months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and 2024 5 Notes to Condensed Consolidated Financial Statements (unaudited) 6 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 18 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 ITEM 4.

Controls and Procedures

Controls and Procedures 26

OTHER INFORMATION

PART II. OTHER INFORMATION ITEM 1.

Legal Proceedings

Legal Proceedings 26 ITEM 1A.

Risk Factors

Risk Factors 27 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 27 ITEM 3. Defaults Upon Senior Securities 27 ITEM 4. Mine Safety Disclosures 27 ITEM 5. Other Information 27 ITEM 6. Exhibits 27

SIGNATURES

SIGNATURES 28 1 PART I

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS CHARLIE ' S HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share amounts) September 30, December 31, 2025 2024 (Unaudited) ASSETS Current assets: Cash $ 1,150 $ 211 Accounts receivable, net 1,149 365 Inventories, net 4,252 2,667 Prepaid expenses and other current assets 3,290 477 Total current assets 9,841 3,720 Non-current assets: Property, plant and equipment, net 20 53 Right-of-use asset, net 569 71 Other assets 128 101 Total non-current assets 717 225 TOTAL ASSETS $ 10,558 $ 3,945 LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses $ 3,744 $ 3,396 Notes payable, net - 520 Notes payable - related parties 2,481 1,488 Lease liabilities 163 73 Deferred revenue 374 98 Total current liabilities 6,762 5,575 Non-current liabilities: Note payable, net of current portion 150 150 Lease liabilities, net of current portion 407 - Total non-current liabilities 557 150 Total liabilities 7,319 5,725 COMMITMENTS AND CONTINGENCIES (see Note 12) Stockholders' equity (deficit): Convertible preferred stock ($ 0.001 par value); 1,800,000 shares authorized Series A, 300,000 shares designated; 94,278 and 122,930 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively - - Series B, 1,500,000 shares designated; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively - - Common stock ($ 0.001 par value); 500,000,000 shares authorized; 270,568,616 and 257,286,631 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 270 257 Additional paid-in capital 11,300 10,662 Accumulated deficit ( 8,331 ) ( 12,699 ) Total stockholders' equity (deficit) 3,239 ( 1,780 ) TOTAL LIABILITIES AND STOCKHOLDERS' EQU

View Full Filing

View this 10-Q filing on SEC EDGAR